Company Insights

GYRE customer relationships

Explore interactive graphBrowse insights index
GYRE customer relationship map

Gyre Therapeutics (GYRE): Customer Concentration, Distribution Dynamics, and Receivables that Matter

Gyre Therapeutics monetizes by manufacturing and selling small‑molecule therapeutics—principally ETUARY (pirfenidone)—through a single‑layer distributor network in the PRC, and by preparing near‑term commercial launches for nintedanib and avatrombopag; revenue is generated at the point of sale to distributors and is heavily concentrated in a small number of Chinese pharmaceutical groups. Investors should evaluate Gyre as a commercialized biopharma whose top-line stability depends on distributor relationships and reimbursement/policy drivers in the PRC, while receivable items from strategic transactions introduce balance‑sheet idiosyncrasies. Learn more about how we surface this intelligence at https://nullexposure.com/.

What the customer map tells you about Gyre’s business model

Gyre operates a classic commercial‑stage pharma model in China: it manufactures and sells to distributors (who resell into hospitals and pharmacies), recognizes revenue at delivery, offers standard short credit terms, and relies on a handful of large customers for most receivables and revenue. Key monetization drivers are product mix (ETUARY >> other products), distributor coverage, provincial tender outcomes, and PRC reimbursement policy.

  • Gyre sells primarily to distributors and recognizes revenue at a point in time when control transfers on delivery. According to the FY2024 Form 10‑K, sales to distributors accounted for 100% of ETUARY revenue and ETUARY represented roughly 99% of total company revenue.
  • Concentration risk is acute: one distributor alone dominates accounts receivable and a small set of distributors dominate revenue. That concentration converts operational or policy shocks into material P&L volatility.
  • Contracting posture is mixed: the company uses short credit terms (typically within three months) and spot, point‑of‑sale recognition for product sales, while certain disposal or hold‑back items (notably the GCBP transaction) are treated as long‑term receivables. These characteristics drive working‑capital dynamics and liquidity sensitivity.

Explore full coverage of supplier, customer and receivable risks at https://nullexposure.com/.

Constraints and what they imply for investors

Gyre’s public disclosures reveal operating constraints that shape durability and risk:

  • Contracting posture: The company combines spot product sales (point‑in‑time revenue recognition) with short trade credit (credit periods usually within three months), producing predictable near‑term cash conversion under normal conditions. Separately, certain deal‑related receivables are classified as long‑term (the GCBP hold‑back is explicitly treated as a long‑term receivable/loan held for investment). These mixed tenors create both steady operating cash flow and isolated long‑dated balance‑sheet exposures.
  • Concentration and criticality: ETUARY drives the business—sales of ETUARY accounted for 99.3% of revenue in 2024—and a few distributors account for most revenue and receivables, a structural single‑counterparty risk that is labeled critical in filings.
  • Maturity: Relationships with major distributors are commercially mature (ETUARY has been marketed in the PRC since 2011 and maintains dominant share), while launches for nintedanib and avatrombopag are in prospect/ramping stages for 2025.
  • Geographic concentration: Revenue and commercial activity are concentrated in the PRC (APAC), with strategic intent to address the U.S. market for F351, exposing Gyre to both PRC policy risk and U.S. reimbursement uncertainty.

Customer and counterparty relationships — the full list and what each means

Below are every relationship referenced in the public search results, each summarized in plain language with source attribution.

Sinopharm Group Co., Ltd.

Sinopharm is Gyre’s largest single customer and accounted for approximately 48.5% of total revenue in FY2024 and 54.3% of accounts receivable at year‑end 2024, making it the principal demand and credit counterparty in Gyre’s commercial footprint. According to Gyre’s FY2024 Form 10‑K, this level of concentration drives material counterparty exposure and working‑capital sensitivity.

China Resources Pharmaceutical Group Ltd (CRPGF)

China Resources Pharmaceutical Group is the second material customer named in Gyre’s revenue mix, accounting for about 13.6% of total revenue in FY2024; Gyre identifies it by name in its FY2024 10‑K disclosures as one of three customers responsible for a large share of sales. This makes CRPGF a strategically important distributor partner for national coverage.

Shanghai Pharmaceuticals Holding Co., Ltd

Shanghai Pharmaceuticals is the third named customer, representing approximately 10.6% of total revenue in FY2024 per Gyre’s FY2024 10‑K, and thus part of the concentrated top‑three group that collectively accounted for nearly three‑quarters of revenue. Its role reinforces the single‑layer distributor model and regional tender dynamics in Gyre’s revenue base.

GNI (reported as GNID in press materials)

Gyre’s Q2 2025 press release reports a line item for “other receivables from GNI” with an amount shown in the financials (noted as “230” in the GlobeNewswire release). The item is disclosed as an other receivable in the company’s August 11, 2025 business update, indicating an outstanding balance due from this counterparty on Gyre’s balance sheet as of the release. (GlobeNewswire, company release, August 11, 2025.)

GCBP (GC Biopharma Corp.)

Gyre discloses a receivable from GCBP related to an asset sale (a $5.0M hold‑back expected, with a receivable line shown as “4,961” in the Q2 2025 disclosure), and the FY2024 filing explicitly treats the GCBP hold‑back as a long‑term receivable and a loan held for investment, with valuation tied to projected cash‑flow timing and discounting. This is a structural, non‑recurring asset‑sale exposure that Gyre classifies on the balance sheet and references in both the 10‑K and subsequent press materials. (Gyre 2024 Form 10‑K; GlobeNewswire company release, August 11, 2025.)

Bottom line for investors: where the risk and optionality live

  • Revenue stability depends on a small set of large distributors (Sinopharm, China Resources, Shanghai Pharmaceuticals), making top‑line and AR behavior highly sensitive to procurement tenders, provincial price controls, and distributor payment behavior.
  • Operational model mixes spot sales with isolated long‑dated receivables (notably the GCBP hold‑back), so cash conversion can be stable during normal trade cycles but exposed to idiosyncratic settlement timing on transaction‑level receivables.
  • Product and geographic concentration amplify policy risk: ETUARY sales in the PRC drive near‑term earnings while regulatory, reimbursement, and centralized procurement policies directly impact margins and volumes.

If you assess counterparties or model working capital for Gyre, focus on the top‑three distributor agreements, AR aging tied to Sinopharm, and the treatment and collectability of the GCBP receivable. For deeper customer and receivable analytics, visit https://nullexposure.com/.

Recommended investor actions

  • Stress‑test revenue and cash flow under scenarios where Sinopharm reduces purchases or extends payment terms.
  • Monitor provincial tender outcomes and NRDL status for ETUARY, and follow any collections updates for the GCBP hold‑back.
  • Track commercialization progress and uptake for nintedanib and avatrombopag as potential de‑risking levers for single‑product dependence.

For a tailored counterparty risk briefing or to integrate Gyre relationship signals into portfolio due diligence, see our coverage at https://nullexposure.com/.